Your browser doesn't support javascript.
loading
Effects of lixisenatide treatment on mild cachexia and related metabolic abnormalities in Walker-256 tumour-bearing rats.
Quintilhano, Débora L; Miksza, Daniele R; Biazi, Giuliana R; Frasson-Uemura, Isabele G; Graciano, Maria Fernanda R; Mazzuco, Tânia L; Carpinelli, Ângelo R; de Souza, Helenir M; Bertolini, Gisele L.
Afiliación
  • Quintilhano DL; Department of Physiological Sciences, State University of Londrina, Londrina, Brazil.
  • Miksza DR; Department of Physiological Sciences, State University of Londrina, Londrina, Brazil.
  • Biazi GR; Department of Physiological Sciences, State University of Londrina, Londrina, Brazil.
  • Frasson-Uemura IG; Department of Physiological Sciences, State University of Londrina, Londrina, Brazil.
  • Graciano MFR; Department of Physiological Sciences, State University of Londrina, Londrina, Brazil.
  • Mazzuco TL; Department of Clinical Medicine, State University of Londrina, Londrina, Brazil.
  • Carpinelli ÂR; Department of Physiology and Biophysics, University of São Paulo, São Paulo, Brazil.
  • de Souza HM; Department of Physiological Sciences, State University of Londrina, Londrina, Brazil.
  • Bertolini GL; Department of Physiological Sciences, State University of Londrina, Londrina, Brazil.
Cell Biochem Funct ; 39(2): 335-343, 2021 Mar.
Article en En | MEDLINE | ID: mdl-32911572
Lixisenatide, a glucagon-like peptide-1 (GLP-1) receptor agonist, is used in the treatment of type 2 diabetes mellitus (T2DM). It increases insulin (INS) secretion and can decrease INS resistance, improving metabolic disorders in this disease. However, its effects on metabolic disturbances in cancer-bearing, which also exhibit decreased INS secretion and INS resistance, changes that may contribute to weight loss (cachexia), have not yet been evaluated. The purpose of this study was to investigate the lixisenatide treatment effects on mild cachexia and related metabolic abnormalities in Walker-256 tumour-bearing rats. Lixisenatide (50 µg kg-1 , SC) was administered once daily, for 6 days, after inoculation of Walker-256 tumour cells. Acute lixisenatide treatment did not improve hypoinsulinemia, INS secretion and INS resistance of tumour-bearing rats. It also did not prevent the reduced glucose and increased triacylglycerol and lactate in the blood and nor the loss of retroperitoneal and epididymal fat of these animals. However, acute lixisenatide treatment accentuated the body mass loss of tumour-bearing rats. Therefore, lixisenatide, unlike T2DM, does not improve hypoinsulinemia and INS resistance associated with cancer, evidencing that it does not have the same beneficial effects in these two diseases. In addition, lixisenatide aggravated weight loss of tumour-bearing rats, suggesting that its use for treatment of T2DM patients with cancer should be avoided. SIGNIFICANCE OF THE STUDY: Lixisenatide increases insulin secretion and appears to reduce insulin resistance in T2DM. However, lixisenatide treatment does not improve hypoinsulinemia and insulin resistance associated with cancer, as it does in T2DM, and aggravated weight loss, suggesting that its use for treatment of T2DM patients with cancer should be avoided.
Asunto(s)
Palabras clave
Texto completo
Añadir a Mi BVS
Imprimir
XML
PubMed Links
Buscar en Google

Texto completo: 1 Colección: 01-internacional Base de datos: MEDLINE Asunto principal: Péptidos / Secreción de Insulina / Hipoglucemiantes Límite: Animals / Humans / Male Idioma: En Revista: Cell Biochem Funct Año: 2021 Tipo del documento: Article País de afiliación: Brasil Pais de publicación: Reino Unido
Texto completo
Añadir a Mi BVS
Imprimir
XML
PubMed Links
Buscar en Google

Texto completo: 1 Colección: 01-internacional Base de datos: MEDLINE Asunto principal: Péptidos / Secreción de Insulina / Hipoglucemiantes Límite: Animals / Humans / Male Idioma: En Revista: Cell Biochem Funct Año: 2021 Tipo del documento: Article País de afiliación: Brasil Pais de publicación: Reino Unido